| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514255020 | Chalcogen bonded directly to a piperazine ring carbon | 25 |
| 20080221123 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment - The present invention relates to piperazinone compounds, pharmaceutical compositions containing those compounds and methods of treating tumors and cancer, among other disease states and conditions in mammalian patients, especially including humans. | 09-11-2008 |
| 20090054460 | Piperazine derivatives and methods of use - Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 02-26-2009 |
| 20090069344 | Modulators of hcv replication - The present invention is directed to compounds of formula (I): | 03-12-2009 |
| 20090170871 | IL-8 Receptor Antagonists - This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). | 07-02-2009 |
| 20090286807 | CYCLIC AMINE COMPOUND - The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: | 11-19-2009 |
| 20090286808 | Opsin Stabilizing Compounds and Methods of Use - The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described. | 11-19-2009 |
| 20100010011 | COMPOUNDS THAT ACT AS A VEHICLE FOR DELIVERY THROUGH THE BLOOD-BRAIN BARRIER AND CHARGE DELIVERY VEHICLE CONSTRUCTIONS - Compounds of formula (I), where R | 01-14-2010 |
| 20100048590 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS - Disclosed are compounds of the formula (I): | 02-25-2010 |
| 20100105698 | Therapeutic Methods and Compounds - The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation. | 04-29-2010 |
| 20100273813 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 10-28-2010 |
| 20110112113 | METHODS OF PREDICTING AND TREATING ADVERSE CARDIAC EVENTS - The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject. | 05-12-2011 |
| 20110166157 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease - The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them. | 07-07-2011 |
| 20120022081 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 01-26-2012 |
| 20120157473 | THERAPEUTIC METHODS AND COMPOUNDS - The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation. | 06-21-2012 |
| 20120232098 | METHODS OF PREDICTING AND TREATING ADVERSE CARDIAC EVENTS - The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject. | 09-13-2012 |
| 20120283270 | EXTRACTS AND BEVERAGES CONTAINING 2,5-PIPERAZINEDIONE,3,6-BIS(PHENYLMETHYL)-, (3S,6S)- - The present invention aims to provide extracts or beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)—, which is a useful substance with an improving effect on learning motivation, in an easy-to-ingest form and at a high concentration. Extracts or beverages whose ratio between the content of 2,5-piperazinedione,3,6-bis(phenyl-methyl)-,(3S,6S)— (unit: μg/100 g) and Brix(Bx) is 6 (μg/100 g)/Bx or more can be ingested continuously over a long period of time as foods and beverages useful for improvement of learning motivation. | 11-08-2012 |
| 20130345238 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 12-26-2013 |
| 20140073649 | ISOTOPICALLY ENRICHED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disease, disorder, or condition. | 03-13-2014 |
| 20140213597 | Methods of Predicting and Treating Adverse Cardiac Events - The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject. | 07-31-2014 |
| 20150051223 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 02-19-2015 |
| 20150051224 | THERAPEUTIC METHODS AND COMPOUNDS - The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation. | 02-19-2015 |
| 20150133470 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS - Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction. | 05-14-2015 |
| 20150315158 | ISOTOPICALLY ENRICHED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disease, disorder, or condition. | 11-05-2015 |
| 20160002178 | POLYAMINE-FATTY ACID DERIVED LIPIDOIDS AND USES THEREOF - The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R—C(═O)—O— moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and/or for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders. | 01-07-2016 |
| 20170232001 | METHOD AND COMPOSITION FOR TREATING MIGRAINES | 08-17-2017 |
